About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 826706, 17 pages
http://dx.doi.org/10.1155/2013/826706
Review Article

Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes

Department of Biochemistry, School of Life Sciences, University of KwaZulu Natal, Westville Campus, Block F3, University Road, Private Bag X54001, Durban 4000, South Africa

Received 11 December 2012; Accepted 21 February 2013

Academic Editor: Thomas Van Groen

Copyright © 2013 Karen Pillay and Patrick Govender. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Reynaud, “Protein misfolding and degenerative diseases,” Nature Education, vol. 3, no. 9, article 28, 2010.
  2. J. C. Sacchettini and J. W. Kelly, “Therapeutic strategies for human amyloid diseases,” Nature Reviews Drug Discovery, vol. 1, no. 4, pp. 267–275, 2002. View at Scopus
  3. J. Ghiso and B. Frangione, “Amyloidosis and Alzheimer's disease,” Advanced Drug Delivery Reviews, vol. 54, no. 12, pp. 1539–1551, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Rahimi, A. Shanmugam, and G. Bitan, “Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders,” Current Alzheimer Research, vol. 5, no. 3, pp. 319–341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Broersen, F. Rousseau, and J. Schymkowitz, “The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?” Alzheimers Research and Therapy, vol. 2, no. 4, pp. 1–14, 2010. View at Publisher · View at Google Scholar
  6. Y. Miller, B. Ma, and R. Nussinov, “Polymorphism in alzheimer Aβ amyloid organization reflects conformational selection in a rugged energy landscape,” Chemical Reviews, vol. 110, no. 8, pp. 4820–4838, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Nakamura and S. A. Lipton, “Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer's and Parkinson's diseases,” Apoptosis, vol. 15, no. 11, pp. 1354–1363, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Humpel, “Identifying and validating biomarkers for Alzheimer's disease,” Trends in Biotechnology, vol. 29, no. 1, pp. 26–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. V. T. Marchesi, “Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy,” FASEB Journal, vol. 25, no. 1, pp. 5–13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Dillin and E. Cohen, “Ageing and protein aggregation-mediated disorders: from invertebrates to mammals,” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 366, no. 1561, pp. 94–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. J. Lee, H. S. Lim, E. Masliah, and H. J. Lee, “Protein aggregate spreading in neurodegenerative diseases: problems and perspectives,” Neuroscience Research, vol. 70, no. 4, pp. 339–348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Brown and J. A. Mastrianni, “The prion diseases,” Journal of Geriatric Psychiatry and Neurology, vol. 23, no. 4, pp. 277–298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Kapurniotu, “Amyloidogenicity and cytotoxicity of islet amyloid polypeptide,” Biopolymers, vol. 60, no. 6, pp. 438–459, 2001. View at Publisher · View at Google Scholar
  14. W. Q. Qiu and M. F. Folstein, “Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis,” Neurobiology of Aging, vol. 27, no. 2, pp. 190–198, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Haataja, T. Gurlo, C. J. Huang, and P. C. Butler, “Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis,” Endocrine Reviews, vol. 29, no. 3, pp. 303–316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Khemtémourian, J. A. Killian, J. W. Höppener, and M. F. Engel, “Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in beta-cell death in type 2 diabetes mellitus,” Experimental Diabetes Research, vol. 2008, Article ID 421287, 2008. View at Scopus
  17. E. Ahmad, A. Ahmad, S. Singh, M. Arshad, A. H. Khan, and R. H. Khan, “A mechanistic approach for islet amyloid polypeptide aggregation to develop anti-amyloidogenic agents for type-2 diabetes,” Biochimie, vol. 93, no. 5, pp. 793–805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Westermark, “Amyloid in the islets of Langerhans: thoughts and some historical aspects,” Upsala Journal of Medical Sciences, vol. 116, no. 2, pp. 81–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. WHO, Diabetes Fact Sheet, May 2012, http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
  20. W. F. Ganong, Review of Medical Physiology, Lange Medical Books/McGraw Hill, Toronto, Canada, 21st edition, 2003.
  21. G. J. S. Cooper, A. C. Willis, A. Clark, R. C. Turner, R. B. Sim, and K. B. M. Reid, “Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 23, pp. 8628–8632, 1987. View at Scopus
  22. M. Krampert, J. Bernhagen, J. Schmucker et al., “Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP),” Chemistry and Biology, vol. 7, no. 11, pp. 855–871, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Martin, “The physiology of amylin and insulin: maintaining the balance between glucose secretion and glucose uptake,” Diabetes Educator, vol. 32, no. 3, pp. 101–104, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Kogire, J. Ishizuka, J. C. Thompson, and G. H. Greeley, “Inhibitory action of islet amyloid polypeptide and calcitonin gene-related peptide on release of insulin from the isolated perfused rat pancreas,” Pancreas, vol. 6, no. 4, pp. 459–463, 1991. View at Scopus
  25. P. Degano, R. A. Silvestre, M. Salas, E. Peiro, and J. Marco, “Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas,” Regulatory Peptides, vol. 43, no. 1-2, pp. 91–96, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. T. J. Rink, K. Beaumont, J. Koda, and A. Young, “Structure and biology of amylin,” Trends in Pharmacological Sciences, vol. 14, no. 4, pp. 113–118, 1993. View at Scopus
  27. T. Zhu, Y. Wang, B. He, J. Zang, Q. He, and W. Zhang, “Islet amyloid polypeptide acts on glucose- stimulated beta cells to reduce voltage-gated calcium channel activation, intracellular Ca2+ concentration, and insulin secretion,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 1, pp. 28–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. G. J. S. Cooper, “Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease,” Endocrine Reviews, vol. 15, no. 2, pp. 163–201, 1994. View at Publisher · View at Google Scholar · View at Scopus
  29. D. F. Kruger, P. M. Gatcomb, and S. K. Owen, “Clinical implications of amylin and amylin deficiency,” Diabetes Educator, vol. 25, no. 3, pp. 389–397, 1999. View at Scopus
  30. R. A. Silvestre, J. Rodríguez-Gallardo, C. Jodka et al., “Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas,” American Journal of Physiology—Endocrinology and Metabolism, vol. 280, no. 3, pp. E443–E449, 2001. View at Scopus
  31. B. Åkesson, G. Panagiotidis, P. Westermark, and I. Lundquist, “Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets,” Regulatory Peptides, vol. 111, no. 1–3, pp. 55–60, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. R. L. Hull, S. Andrikopoulos, C. B. Verchere et al., “Increased dietary fat promotes islet amyloid formation and β-cell secretory dysfunction in a transgenic mouse model of islet amyloid,” Diabetes, vol. 52, no. 2, pp. 372–379, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. J. W. Höppener, H. M. Jacobs, N. Wierup et al., “Human islet amyloid polypeptide transgenic mice: in vivo and ex vivo models for the role of hIAPP in type 2 diabetes mellitus,” Experimental Diabetes Research, vol. 2008, Article ID 697035, 2008. View at Scopus
  34. R. Kodali and R. Wetzel, “Polymorphism in the intermediates and products of amyloid assembly,” Current Opinion in Structural Biology, vol. 17, no. 1, pp. 48–57, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Westermark, U. Engstrom, K. H. Johnson, G. T. Westermark, and C. Betsholtz, “Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 13, pp. 5036–5040, 1990. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Tenidis, M. Waldner, J. Bernhagen et al., “Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties,” Journal of Molecular Biology, vol. 295, no. 4, pp. 1055–1071, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. L. A. Scrocchi, Y. Chen, S. Waschuk et al., “Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis,” Journal of Molecular Biology, vol. 318, no. 3, pp. 697–706, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Mazor, S. Gilead, I. Benhar, and E. Gazit, “Identification and characterization of a novel molecular-recognition and self-assembly domain within the islet amyloid polypeptide,” Journal of Molecular Biology, vol. 322, no. 5, pp. 1013–1024, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. E. T. A. S. Jaikaran, C. E. Higham, L. C. Serpell et al., “Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis,” Journal of Molecular Biology, vol. 308, no. 3, pp. 515–525, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. V. Kajava, U. Aebi, and A. C. Steven, “The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin,” Journal of Molecular Biology, vol. 348, no. 2, pp. 247–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Luca, W. M. Yau, R. Leapman, and R. Tycko, “Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR,” Biochemistry, vol. 46, no. 47, pp. 13505–13522, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. R. Nilsson and D. P. Raleigh, “Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin,” Journal of Molecular Biology, vol. 294, no. 5, pp. 1375–1385, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Goldsbury, K. Goldie, J. Pellaud et al., “Amyloid fibril formation from full-length and fragments of amylin,” Journal of Structural Biology, vol. 130, no. 2-3, pp. 352–362, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Azriel and E. Gazit, “Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 34156–34161, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. L. A. Scrocchi, K. Ha, Y. Chen, L. Wu, F. Wang, and P. E. Fraser, “Identification of minimal peptide sequences in the (8-20) domain of human islet amyloid polypeptide involved in fibrillogenesis,” Journal of Structural Biology, vol. 141, no. 3, pp. 218–227, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. O. V. Galzitskaya, S. O. Garbuzynskiy, and M. Y. Lobanov, “Is it possible to predict amyloidogenic regions from sequence alone?” Journal of Bioinformatics and Computational Biology, vol. 4, no. 2, pp. 373–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. Z. Zhang, H. Chen, and L. Lai, “Identification of amyloid fibril-forming segments based on structure and residue-based statistical potential,” Bioinformatics, vol. 23, no. 17, pp. 2218–2225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. S. H. Shim, R. Gupta, Y. L. Ling, D. B. Strasfeld, D. P. Raleigh, and M. T. Zanni, “Two-dimensional IR spectroscopy and isotope labeling defines the pathway of amyloid formation with residue-specific resolution,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 16, pp. 6614–6619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Gazit, “A possible role for π-stacking in the self-assembly of amyloid fibrils,” FASEB Journal, vol. 16, no. 1, pp. 77–83, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. C. M. Dobson, “Protein folding and misfolding,” Nature, vol. 426, no. 6968, pp. 884–890, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. P. T. Lansbury and B. Caughey, “The chemistry of scrapie infection: implications of the ice 9' metaphor,” Chemistry and Biology, vol. 2, no. 1, pp. 1–5, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Kayed, J. Bernhagen, N. Greenfield et al., “Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro,” Journal of Molecular Biology, vol. 287, no. 4, pp. 781–796, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Goldsbury, J. Kistler, U. Aebi, T. Arvinte, and G. J. S. Cooper, “Watching amyloid fibrils grow by time-lapse atomic force microscopy,” Journal of Molecular Biology, vol. 285, no. 1, pp. 33–39, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. T. L. S. Benzinger, D. M. Gregory, T. S. Burkoth et al., “Two-dimensional atructure of â-amyloid(10–35) fibrils,” Biochemistry, vol. 39, pp. 3491–3499, 2000. View at Publisher · View at Google Scholar
  55. R. Tycko, “Progress towards a molecular-level structural understanding of amyloid fibrils,” Current Opinion in Structural Biology, vol. 14, no. 1, pp. 96–103, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. S. A. Jayasinghe and R. Langen, “Lipid membranes modulate the structure of islet amyloid polypeptide,” Biochemistry, vol. 44, no. 36, pp. 12113–12119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Nelson, M. R. Sawaya, M. Balbirnie et al., “Structure of the cross-β spine of amyloid-like fibrils,” Nature, vol. 435, no. 7043, pp. 773–778, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. M. P. Mattson and Y. Goodman, “Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium,” Brain Research, vol. 676, no. 1, pp. 219–224, 1995. View at Publisher · View at Google Scholar · View at Scopus
  59. T. A. Mirzabekov, M. C. Lin, and B. L. Kagan, “Pore formation by the cytotoxic islet amyloid peptide amylin,” The Journal of Biological Chemistry, vol. 271, no. 4, pp. 1988–1992, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Tomiyama, H. Kaneko, K. I. Kataoka, S. Asano, and N. Endo, “Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction,” Biochemical Journal, vol. 322, no. 3, pp. 859–865, 1997. View at Scopus
  61. A. Kapurniotu, J. Bernhagen, N. Greenfield et al., “Contribution of advanced glycosylation to the amyloidogenicity of islet and amyloid polypeptide,” European Journal of Biochemistry, vol. 251, no. 1-2, pp. 208–216, 1998. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Z. Bai, E. L. Saafi, S. Zhang, and G. J. S. Cooper, “Role of Ca2+ in apoptosis evoked by human amylin in pancreatic islet β-cells,” Biochemical Journal, vol. 343, no. 1, pp. 53–61, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. H. J. Hiddinga and N. L. Eberhardt, “Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells,” American Journal of Pathology, vol. 154, no. 4, pp. 1077–1088, 1999. View at Scopus
  64. A. Kapurniotu, A. Schmauder, and K. Tenidis, “Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity,” Journal of Molecular Biology, vol. 315, no. 3, pp. 339–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Tatarek-Nossol, L. M. Yan, A. Schmauder, K. Tenidis, G. Westermark, and A. Kapurniotu, “Inhibition of hIAPP amyloid-fibril formation and apoptotic cell death by a designed hIAPP amyloid-core-containing hexapeptide,” Chemistry & Biology, vol. 12, no. 7, pp. 797–809, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. L. M. Yan, A. Velkova, M. Tatarek-Nossol, E. Andreetto, and A. Kapurniotu, “IAPP mimic blocks Aβ cytotoxic self-assembly: cross-suppression of amyloid toxicity of Aβ and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes,” Angewandte Chemie—International Edition, vol. 46, no. 8, pp. 1246–1252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Janson, R. H. Ashley, D. Harrison, S. McIntyre, and P. C. Butler, “The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles,” Diabetes, vol. 48, no. 3, pp. 491–498, 1999. View at Scopus
  68. M. Anguiano, R. J. Nowak, and P. T. Lansbury, “Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes,” Biochemistry, vol. 41, no. 38, pp. 11338–11343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. R. Kayed, Y. Sokolov, B. Edmonds et al., “Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases,” Journal of Biological Chemistry, vol. 279, no. 45, pp. 46363–46366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Konarkowska, J. F. Aitken, J. Kistler, S. Zhang, and G. J. S. Cooper, “The aggregation potential of human amylin determines its cytotoxicity towards islet β-cells,” FEBS Journal, vol. 273, no. 15, pp. 3614–3624, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. J. J. Meier, R. Kayed, C. Y. Lin et al., “Inhibition of human IAPP fibril formation does not prevent β-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP,” American Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 6, pp. E1317–E1324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. R. A. Ritzel, J. J. Meier, C. Y. Lin, J. D. Veldhuis, and P. C. Butler, “Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets,” Diabetes, vol. 56, no. 1, pp. 65–71, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. J. F. Aitken, K. M. Loomes, D. W. Scott et al., “Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice,” Diabetes, vol. 59, no. 1, pp. 161–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. J. J. Meier, R. Kayed, C. Y. Lin et al., “Inhibition of human IAPP fibril formation does not prevent β-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP,” American Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 6, pp. E1317–E1324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Lorenzo, B. Razzaboni, G. C. Weir, and B. A. Yankner, “Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus,” Nature, vol. 368, no. 6473, pp. 756–760, 1994. View at Publisher · View at Google Scholar · View at Scopus
  76. M. F. M. Sciacca, M. Pappalardo, F. Attanasio, D. Milardi, C. La Rosa, and D. M. Grasso, “Are fibril growth and membrane damage linked processes? An experimental and computational study of IAPP12-18 and IAPP21-27 peptides,” New Journal of Chemistry, vol. 34, no. 2, pp. 200–207, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Demuro, E. Mina, R. Kayed, S. C. Milton, I. Parker, and C. G. Glabe, “Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 17294–17300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. J. D. Knight and A. D. Miranker, “Phospholipid catalysis of diabetic amyloid assembly,” Journal of Molecular Biology, vol. 341, no. 5, pp. 1175–1187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. D. H. J. Lopes, A. Meister, A. Gohlke, A. Hauser, A. Blume, and R. Winter, “Mechanism of islet amyloid polypeptide fibrillation at lipid interfaces studied by infrared reflection absorption spectroscopy,” Biophysical Journal, vol. 93, no. 9, pp. 3132–3141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Sparr, M. F. M. Engel, D. V. Sakharov et al., “Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers,” FEBS Letters, vol. 577, no. 1-2, pp. 117–120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. M. F. M. Engel, H. Yigittop, R. C. Elgersma et al., “Islet amyloid polypeptide inserts into phospholipid monolayers as monomer,” Journal of Molecular Biology, vol. 356, no. 3, pp. 783–789, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. M. F. M. Engel, L. Khemtémourian, C. C. Kleijer et al., “Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 16, pp. 6033–6038, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. M. F. M. Engel, “Membrane permeabilization by islet amyloid polypeptide,” Chemistry and Physics of Lipids, vol. 160, no. 1, pp. 1–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Schubert, C. Behl, R. Lesley et al., “Amyloid peptides are toxic via a common oxidative mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 6, pp. 1989–1993, 1995. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Dash, Cell Death, July 2009, http://www.sgul.ac.uk/depts/immunology/~dash/apoptosis/index.htm.
  86. S. Zhang, J. Liu, E. L. Saafi, and G. J. S. Cooper, “Induction of apoptosis by human amylin in RINm5F islet β-cells is associated with enhanced expression of p53 and p21(WAF1/CIP1),” FEBS Letters, vol. 455, no. 3, pp. 315–320, 1999. View at Publisher · View at Google Scholar · View at Scopus
  87. E. L. Saafi, B. Konarkowska, S. Zhang, J. Kistler, and G. J. S. Cooper, “Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet β-cells,” Cell Biology International, vol. 25, no. 4, pp. 339–350, 2001. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Zhang, J. Liu, G. MacGibbon, M. Dragunow, and G. J. S. Cooper, “Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet β-cells,” Journal of Molecular Biology, vol. 324, no. 2, pp. 271–285, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. C. J. Huang, L. Haataja, T. Gurlo et al., “Induction of endoplasmic reticulum stress-induced β-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide,” American Journal of Physiology—Endocrinology and Metabolism, vol. 293, no. 6, pp. E1656–E1662, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Zhang, H. Liu, H. Yu, and G. J. S. Cooper, “Fas-associated death receptor signaling evoked by human amylin in islet β-cellsd,” Diabetes, vol. 57, no. 2, pp. 348–356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. C. J. Huang, T. Gurlo, L. Haataja et al., “Calcium-activated calpain-2 is a mediator of beta cell dysfunction and apoptosis in type 2 diabetes,” Journal of Biological Chemistry, vol. 285, no. 1, pp. 339–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. H. M. Tucker, R. E. Rydel, S. Wright, and S. Estus, “Human amylin induces 'apoptotic' pattern of gene expression concomitant with cortical neuronal apoptosis,” Journal of Neurochemistry, vol. 71, no. 2, pp. 506–516, 1998. View at Scopus
  93. T. Gurlo, S. Ryazantsev, C. J. Huang et al., “Evidence for proteotoxicity in β cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway,” American Journal of Pathology, vol. 176, no. 2, pp. 861–869, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. A. Lim, V. Rhein, G. Baysang et al., “Aβ and human amylin share a common toxicity pathway via mitochondrial dysfunction,” Proteomics, vol. 10, no. 8, pp. 1621–1633, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. J. F. Aitken, K. M. Loomes, B. Konarkowska, and G. J. S. Cooper, “Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid,” Biochemical Journal, vol. 374, no. 3, pp. 779–784, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. J. H. Cooper, “Selective amyloid staining as a function of amyloid composition and structure. Histochemical analysis of the alkaline Congo red, standardized toluidine blue, and iodine methods,” Laboratory Investigation, vol. 31, no. 3, pp. 232–238, 1974. View at Scopus
  97. P. T. Lansbury, “In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information,” Biochemistry, vol. 31, no. 30, pp. 6865–6870, 1992. View at Scopus
  98. M. R. Nilsson, “Techniques to study amyloid fibril formation in vitro,” Methods, vol. 34, no. 1, pp. 151–160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. M. R. Nilsson, M. Driscoll, and D. P. Raleigh, “Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation,” Protein Science, vol. 11, no. 2, pp. 342–349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Radovan, N. Opitz, and R. Winter, “Fluorescence microscopy studies on islet amyloid polypeptide fibrillation at heterogeneous and cellular membrane interfaces and its inhibition by resveratrol,” FEBS Letters, vol. 583, no. 9, pp. 1439–1445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. H. LeVine, “Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution,” Protein Science, vol. 2, no. 3, pp. 404–410, 1993. View at Scopus
  102. I. T. Yonemoto, G. J. A. Kroon, H. J. Dyson, W. E. Balch, and J. W. Kelly, “Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state,” Biochemistry, vol. 47, no. 37, pp. 9900–9910, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. L. M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, and A. Kapurniotu, “Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2046–2051, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Bedrood, S. Jayasinghe, D. Sieburth et al., “Annexin A5 directly interacts with amyloidogenic proteins and reduces their toxicity,” Biochemistry, vol. 48, no. 44, pp. 10568–10576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Khurana, C. Coleman, C. Ionescu-Zanetti et al., “Mechanism of thioflavin T binding to amyloid fibrils,” Journal of Structural Biology, vol. 151, no. 3, pp. 229–238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Porat, Y. Mazor, S. Efrat, and E. Gazit, “Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions,” Biochemistry, vol. 43, no. 45, pp. 14454–14462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. C. S. Goldsbury, G. J. S. Cooper, K. N. Goldie et al., “Polymorphic fibrillar assembly of human amylin,” Journal of Structural Biology, vol. 119, no. 1, pp. 17–27, 1997. View at Publisher · View at Google Scholar · View at Scopus
  108. J. D. Green, C. Goldsbury, J. Kistler, G. J. S. Cooper, and U. Aebi, “Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 12206–12212, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Cort, Z. Liu, G. Lee et al., “β-structure in human amylin and two designer β-peptides: CD and NMR spectroscopic comparisons suggest soluble β-oligomers and the absence of significant populations of β-strand dimers,” Biochemical and Biophysical Research Communications, vol. 204, no. 3, pp. 1088–1095, 1994. View at Publisher · View at Google Scholar · View at Scopus
  110. L. A. Scrocchi, K. Ha, Y. Chen, L. Wu, F. Wang, and P. E. Fraser, “Identification of minimal peptide sequences in the (8-20) domain of human islet amyloid polypeptide involved in fibrillogenesis,” Journal of Structural Biology, vol. 141, no. 3, pp. 218–227, 2003. View at Publisher · View at Google Scholar · View at Scopus
  111. K. J. Potter, L. A. Scrocchi, G. L. Warnock et al., “Amyloid inhibitors enhance survival of cultured human islets,” Biochimica et Biophysica Acta—General Subjects, vol. 1790, no. 6, pp. 566–574, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. H. Rode, D. Eisel, and I. Frost, Apoptosis, Cell Death, and Cell Proliferation Manual, in Apoptosis, Cell Death, and Cell Proliferation Manual, Roche Applied Science, Indianapolis, Ind, USA, 2007.
  113. A. Zarei and B. Markovic, Refinement in the Use and Data Analysis of the Promega CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega Corporation, 2012, http://www.promega.com/resources/articles/pubhub/enotes/data-analysis-of-the-celltiter-96-aqueous-nonradioactive-cell-proliferation-assay/.
  114. U. Bandyopadhyay, D. Das, and R. K. Banerjee, “Reactive oxygen species: oxidative damage and pathogenesis,” Current Science, vol. 77, no. 5, pp. 658–666, 1999. View at Scopus
  115. E. Gazit, “Mechanisms of amyloid fibril self-assembly and inhibition: model short peptides as a key research tool,” FEBS Journal, vol. 272, no. 23, pp. 5971–5978, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. D. T. S. Rijkers, J. W. M. Hoppener, G. Posthuma, C. J. M. Lips, and R. M. J. Liskamp, “Inhibition of amyloid fibril formation of human amylin by N-alkylated amino acid and -hydroxy acid residue containing peptides,” Chemistry, vol. 8, no. 18, pp. 4285–4291, 2002. View at Publisher · View at Google Scholar
  117. B. Konarkowska, J. F. Aitken, J. Kistler, S. Zhang, and G. J. S. Cooper, “Thiol reducing compounds prevent human amylin-evoked cytotoxicity,” FEBS Journal, vol. 272, no. 19, pp. 4949–4959, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. S. Zraika, R. L. Hull, J. Udayasankar et al., “Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis,” Diabetologia, vol. 52, no. 4, pp. 626–635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. R. Mishra, D. Sellin, D. Radovan, A. Gohlke, and R. Winter, “Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol,” ChemBioChem, vol. 10, no. 3, pp. 445–449, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Jiang, W. Li, J. E. Shea, and Y. Mu, “Resveratrol inhibits the formation of multiple-layered beta-sheet oligomers of the human islet amyloid polypeptide segment 22–27,” Biophysical Journal, vol. 100, no. 8, pp. 2076–2076, 2011. View at Publisher · View at Google Scholar
  121. J. M. Smoliga, J. A. Baur, and H. A. Hausenblas, “Resveratrol and health—a comprehensive review of human clinical trials,” Molecular Nutrition and Food Research, vol. 55, no. 8, pp. 1129–1141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. P. Brasnyo, G. A. Molnar, M. Mohas et al., “Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients,” British Journal of Nutrition, vol. 106, no. 3, pp. 383–389, 2011. View at Publisher · View at Google Scholar
  123. G. Forloni, L. Colombo, L. Girola, F. Tagliavini, and M. Salmona, “Anti-amyloidogenic activity of tetracyclines: studies in vitro,” FEBS Letters, vol. 487, no. 3, pp. 404–407, 2001. View at Publisher · View at Google Scholar · View at Scopus
  124. A. Abedini, F. Meng, and D. P. Raleigh, “A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor,” Journal of the American Chemical Society, vol. 129, no. 37, pp. 11300–11301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. T. Hayashi, T. Asai, and H. Ogoshi, “Conformational analysis of β-turn structure in tetrapeptides containing proline or proline analogs,” Tetrahedron Letters, vol. 38, no. 17, pp. 3039–3042, 1997. View at Publisher · View at Google Scholar · View at Scopus
  126. M. F. Kong, P. King, I. A. Macdonald et al., “Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM,” Diabetologia, vol. 40, no. 1, pp. 82–88, 1997. View at Publisher · View at Google Scholar · View at Scopus
  127. M. F. Kong, T. A. Stubbs, P. King et al., “The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM,” Diabetologia, vol. 41, no. 5, pp. 577–583, 1998. View at Publisher · View at Google Scholar · View at Scopus
  128. R. Thompson, L. Pearson, S. Schoenfeld, and O. Kolterman, “Pramlintide improves glycemic control in patients with type II diabetes requiring insulin,” Diabetologia, vol. 40, pp. 1397–1397, 1997.
  129. R. G. Thompson, L. Pearson, S. L. Schoenfeld, and O. G. Kolterman, “Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin,” Diabetes Care, vol. 21, no. 6, pp. 987–993, 1998. View at Publisher · View at Google Scholar · View at Scopus
  130. R. G. Thompson, A. Gottlieb, K. Organ, J. Koda, J. Kisicki, and O. G. Kolterman, “Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes,” Diabetic Medicine, vol. 14, no. 7, pp. 547–555, 1997. View at Publisher · View at Google Scholar
  131. R. G. Thompson, L. Pearson, and O. G. Kolterman, “Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations,” Diabetologia, vol. 40, no. 11, pp. 1278–1285, 1997. View at Publisher · View at Google Scholar · View at Scopus
  132. M. F. Kong, T. A. Stubbs, P. King et al., “The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM,” Diabetologia, vol. 41, no. 5, pp. 577–583, 1998. View at Publisher · View at Google Scholar · View at Scopus
  133. R. G. Thompson, L. Pearson, S. L. Schoenfeld, and O. G. Kolterman, “Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin,” Diabetes Care, vol. 21, no. 6, pp. 987–993, 1998. View at Publisher · View at Google Scholar · View at Scopus
  134. P. Hollander, R. Ratner, M. Fineman et al., “Addition of pramlintide to insulin therapy lowers HbA1c in conjuction with weight loss in patients with type 2 diabetes approaching glycaemic targets,” Diabetes, Obesity and Metabolism, vol. 5, no. 6, pp. 408–414, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. C. Weyer, D. Maggs, J. Ruggles, M. Fineman, T. Burrell, and O. Kolterman, “The human amylin analog, pramlintide, reduces body weight in insulin-treated patients with type 2 diabetes,” Diabetologia, vol. 46, pp. A295–A295, 2003.
  136. D. G. Maggs, M. Fineman, J. Kornstein et al., “Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study,” Diabetes/Metabolism Research and Reviews, vol. 20, no. 1, pp. 55–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. R. E. Ratner, R. Dickey, M. Fineman et al., “Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial,” Diabetic Medicine, vol. 21, no. 11, pp. 1204–1212, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. G. J. Ryan, L. J. Jobe, and R. Martin, “Pramlintide in the treatment of type 1 and type 2 diabetes mellitus,” Clinical Therapeutics, vol. 27, no. 10, pp. 1500–1512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  139. G. Ryan, T. A. Briscoe, and L. Jobe, “Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes,” Drug Design, Development and Therapy, no. 2, pp. 203–214, 2008. View at Scopus
  140. R. L. Hull, Z. P. Shen, M. R. Watts et al., “Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide,” Diabetes, vol. 54, no. 7, pp. 2235–2244, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. J. M. Ostresh, G. M. Husar, S. E. Blondelle, B. Dorner, P. A. Weber, and R. A. Houghten, “'Libraries from libraries': chemical transformation of combinatorial libraries to extend the range and repertoire of chemical diversity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 23, pp. 11138–11142, 1994. View at Publisher · View at Google Scholar · View at Scopus
  142. K. Muthusamy, P. I. Arvidsson, P. Govender, H. G. Kruger, G. E. M. Maguire, and T. Govender, “Design and study of peptide-based inhibitors of amylin cytotoxicity,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 4, pp. 1360–1362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. E. Albrecht, H. Jones, L. S. L. Gaeta, K. S. Prickett, and K. Beaumont, “Amylin antagonist peptides and uses thereof,” patent number, 1996.
  144. Y. Fezoui and C. Soto-Jara, “Amylin aggregation inhibitors and uses thereof,” patent number, 2007.
  145. C. Cabaleiro-Lago, I. Lynch, K. A. Dawson, and S. Linse, “Inhibition of IAPP and IAPP(20-29) fibrillation by polymeric nanoparticles,” Langmuir, vol. 26, no. 5, pp. 3453–3461, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. F. Meng, A. Abedini, A. Plesner et al., “The sulfated triphenyl methane derivative acid fuchsin is a potent inhibitor of amyloid formation by human islet amyloid polypeptide and protects against the toxic effects of amyloid formation,” Journal of Molecular Biology, vol. 400, no. 3, pp. 555–566, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. S. Rigacci, V. Guidotti, M. Bucciantini et al., “Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin,” Journal of Nutritional Biochemistry, vol. 21, no. 8, pp. 726–735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  148. C. Buzea, I. I. P. Blandino, and K. Robbie, “Nanomaterials and nanoparticles: sources and toxicity,” Biointerphases, vol. 2, no. 4, pp. MR17–MR71, 2007. View at Publisher · View at Google Scholar
  149. A. El-Ansary and S. Al-Daihan, “On the toxicity of therapeutically used nanoparticles: an overview,” Journal of Toxicology, vol. 2009, pp. 1–9, 2009.
  150. C. Soto, E. M. Castaño, R. A. Kumar, R. C. Beavis, and B. Frangione, “Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure,” Neuroscience Letters, vol. 200, no. 2, pp. 105–108, 1995. View at Publisher · View at Google Scholar · View at Scopus
  151. K. Muthusamy, F. Albericio, P. I. Arvidsson et al., “Microwave assisted SPPS of amylin and its toxicity of the pure product to RIN-5F cells,” Biopolymers, vol. 94, no. 3, pp. 323–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. L. Hou, I. Kang, R. E. Marchant, and M. G. Zagorski, “Methionine 35 oxidation reduces fibril assembly of the amyloid aβ-(1–42) peptide of Alzheimer's disease,” Journal of Biological Chemistry, vol. 277, no. 43, pp. 40173–40176, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. V. N. Uversky, G. Yamin, P. O. Souillac, J. Goers, C. B. Glaser, and A. L. Fink, “Methionine oxidation inhibits fibrillation of human α-synuclein in vitro,” FEBS Letters, vol. 517, no. 1–3, pp. 239–244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  154. A. Abedini and D. P. Raleigh, “Incorporation of pseudoproline derivatives allows the facile synthesis of human IAPP, a highly amyloidogenic and aggregation-prone polypeptide,” Organic Letters, vol. 7, no. 4, pp. 693–696, 2005. View at Publisher · View at Google Scholar · View at Scopus
  155. A. Abedini, G. Singh, and D. P. Raleigh, “Recovery and purification of highly aggregation-prone disulfide-containing peptides: application to islet amyloid polypeptide,” Analytical Biochemistry, vol. 351, no. 2, pp. 181–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  156. K. Page, C. A. Hood, H. Patel, G. Fuentes, M. Menakuru, and J. H. Park, “Fast Fmoc synthesis of hAmylin1–37 with pseudoproline assisted on-resin disulfide formation,” Journal of Peptide Science, vol. 13, no. 12, pp. 833–838, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. C. A. Hood, G. Fuentes, H. Patel, K. Page, M. Menakuru, and J. H. Park, “Fast conventional Fmoc solid-phase peptide synthesis with HCTU,” Journal of Peptide Science, vol. 14, no. 1, pp. 97–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. P. Marek, A. M. Woys, K. Sutton, M. T. Zanni, and D. P. Raleigh, “Efficient microwave-assisted synthesis of human islet amyloid polypeptide designed to facilitate the specific incorporation of labeled amino acids,” Organic Letters, vol. 12, no. 21, pp. 4848–4851, 2010. View at Publisher · View at Google Scholar · View at Scopus